Phaseline

Companies › Wigen Biomedicine Technology (Shanghai)

Wigen Biomedicine Technology (Shanghai): clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WJB001
Wee1 inhibitor
–Phase 1Advanced Solid Tumors; Advanced Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05773820WJB001Phase 1Advanced Solid TumorsOncologyDec 2027
NCT06953323WJB001Phase 1Advanced Solid TumorOncologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.